Get our news on your inbox! x

Remember me Forgot password

MercoPress, en Español

Montevideo, May 21st 2024 - 13:02 UTC

Tag: Zalika Farmacêutica

  • Thursday, January 11th 2024 - 11:06 UTC

    Brazilian-developed vaccine against Covid-19 registered by Anvisa

    The recombinant Zalika vaccine is monovalent for the original SARS-CoV-2 virus

    The new vaccine against Covid-19 developed by the Brazilian company Zalika Farmacêutica has been entered into the National Health Surveillance Agency (Anvisa) this week, Agencia Brasil reported. The drug can be used in people aged 12 and over and is to be administered in two doses, 21 days apart, with boosters after 6 months for those over 18 years of age.